Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus.
Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R. Freifeld Y, et al. Among authors: porta c. Urol Oncol. 2022 Apr;40(4):166.e9-166.e13. doi: 10.1016/j.urolonc.2021.12.018. Epub 2022 Feb 8. Urol Oncol. 2022. PMID: 35144866 Free PMC article.
The effect of a treatment delay on outcome in metastatic renal cell carcinoma.
Iacovelli R, Galli L, De Giorgi U, Porta C, Nolè F, Zucali P, Sabbatini R, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Buti S, Massari F, Masini C, Ricotta R, Biasco E, Lolli C, Gri N, Verri E, Miggiano C, Vitale MG, Tortora G. Iacovelli R, et al. Among authors: porta c. Urol Oncol. 2019 Aug;37(8):529.e1-529.e7. doi: 10.1016/j.urolonc.2019.03.005. Epub 2019 Mar 29. Urol Oncol. 2019. PMID: 30935843
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Santoni M, et al. Among authors: porta c. Clin Genitourin Cancer. 2022 Jun;20(3):285-295. doi: 10.1016/j.clgc.2022.02.003. Epub 2022 Feb 19. Clin Genitourin Cancer. 2022. PMID: 35305916
The multispeciality approach to the management of localised kidney cancer.
Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M. Stewart GD, et al. Among authors: porta c. Lancet. 2022 Aug 13;400(10351):523-534. doi: 10.1016/S0140-6736(22)01059-5. Epub 2022 Jul 19. Lancet. 2022. PMID: 35868329 Free article. Review.
[The Treatment of Metastatic Renal Cell Carcinoma: An Update].
Pezzicoli G, Ganini C, Re Sartò GV, Pirovano M, Cosmai L, Porta C. Pezzicoli G, et al. Among authors: porta c. G Ital Nefrol. 2023 Oct 3;40(Suppl 81):2023-S81. G Ital Nefrol. 2023. PMID: 38007832 Review. Italian.
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Gore ME, et al. Among authors: porta c. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
973 results